PERRIGO Co plc (PRGO)
NYSE · Pharmaceuticals & Biotech · Pharmaceutical Preparations
- Price
- $14.31
- Day
- +1.27%
- Market cap
- $1.99B
Close 2026-09-22.
The company
WHO WE ARE Perrigo is a leading pure-play self-care company with more than a century of providing high-quality health and wellness solutions to meet the evolving needs of consumers. As one of the originators of the over-the-counter ("OTC") self-care market, Perrigo is led by its vision "To Provide The Best Self-Care For Everyone" and its purpose to "Make Lives Better Through Trusted Health and Wellness Solutions, Accessible To All". Perrigo works to fulfill its vision and purpose as a top-tier consumer self-care company with a focused portfolio based on consumer-led innovation, which meets societal needs for: • Access : Perrigo's self-care products and solutions enhance the daily lives of millions of families, empowering them to take control of their health and wellness. • Value : Perrigo delivers value by helping consumers proactively manage their well-being through affordable and effective self-care solutions. • Reliability : Perrigo ensures the safety and effectiveness of its self-care solutions, best serving its consumers. Perrigo provides access to trusted self-care solutions that can be used without the need to visit a health practitioner for a prescription.
From Item 1: WHO WE ARE.
By business segment
- Consumer Self Care Americas — 61%
- Consumer Self Care International — 39%
Institutional holders
Largest positions reported on Form 13F for the quarter ended 2026-06-30, by value.
- BlackRock, Inc. — $160.2M
- NEUBERGER BERMAN GROUP LLC — $110.21M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $93.98M
- STATE STREET CORP — $88.66M
- FULLER & THALER ASSET MANAGEMENT, INC. — $77.91M
- VANGUARD CAPITAL MANAGEMENT LLC — $64.89M
- Invesco Ltd. — $59.42M
- DIMENSIONAL FUND ADVISORS LP — $54.28M
Insider trades
Open-market buys and sales filed on Form 4, newest first. Grants, option exercises and tax withholding are left out.
- Parker Geoffrey M. (Director) bought 7,500 shares at $14.18 on 2025-11-12
- Lennox Abigail (EVP and CSO) bought 1,255 shares at $22.41 on 2025-09-08
- Atkinson Charles (EVP, General Counsel & Sec.) bought 1,000 shares at $23.20 on 2025-09-05
- Willis Robert (EVP & CHRO) bought 1,488 shares at $24.10 on 2025-08-22
- Parker Geoffrey M. (Director) bought 4,375 shares at $22.97 on 2025-08-18
- Parker Geoffrey M. (Director) bought 4,375 shares at $22.97 on 2025-08-18
Recent filings
- 4 — 2026-09-15
- 4 — 2026-09-15
- 4 — 2026-09-10
- SCHEDULE 13G/A — 2026-09-08
- SCHEDULE 13G/A — 2026-08-14
- 10-Q — 2026-08-05
- 8-K — 2026-08-05
- SCHEDULE 13G/A — 2026-07-29
- 4 — 2026-07-23
- 4 — 2026-07-15